Tenders

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Bosutinib (L01ea04) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Golimumab (L04ab06) as Part of a So-Called Open House Model.

Landscaping Work, New Construction of Kita Blp

Anonymous, Non-Open, Single-Phase Art Competition with a Preceding, Europe-Wide Open Application Process

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Tapendadol (Excl. Potency 25 Mg in the Standard Size N3), (Obg) Atc N02ax06 F. D. Z. 01.11.24 - 31.10.26

Open House Drug Discount Agreements Sorafenib, Atc L01ex02

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Imiquimod (D06bb10) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Contracts in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Vaginal Ring with Gestagens and Estrogens (G02bb01) as Part of a So-Called Open...

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V with Effect. Allergen Extract of Various Origins (Subcutaneous Syringes; V01aa02, V01aa03, V01aa05), for the Period November 1St, 2024 - October 31S...

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Ebastine (R06ax22) as Part of a So-Called Open House Model.